This inventor holds 2 USPTO granted patents. Top assignees: Pharmacia & Upjohn Company, Other. Active years: 2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 523 
1 out of 834,513 Years Active: 2002
Title: John E Bleasdale: Innovator in Diabetes Treatment
Introduction
John E Bleasdale is a notable inventor based in Portage, MI (US). He has made significant contributions to the field of medical science, particularly in the treatment of Non-Insulin Dependent Diabetes Mellitus (NIDDM). With a total of 2 patents, his work focuses on developing innovative solutions to combat this prevalent condition.
Latest Patents
Bleasdale's latest patents include inhibitors of protein tyrosine phosphatase. The first patent presents small molecular weight, non-peptidic inhibitors of formulae I-VII of Protein Tyrosine Phosphatase 1 (PTP1), which are useful for the treatment and/or prevention of NIDDM. The second patent also involves small molecular weight, non-peptidic inhibitors of formula I and II of PTP1, aimed at the same therapeutic goals.
Career Highlights
Throughout his career, Bleasdale has worked with prominent companies, including Pharmacia & Upjohn Company. His expertise in the field has allowed him to contribute to significant advancements in diabetes treatment.
Collaborations
Some of his notable coworkers include Scott D Larsen and Paul D May. Their collaborative efforts have further enhanced the impact of Bleasdale's inventions.
Conclusion
John E Bleasdale's innovative work in developing inhibitors for diabetes treatment showcases his dedication to improving healthcare solutions. His contributions are vital in the ongoing fight against NIDDM.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile